Literature DB >> 22878619

Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?

Lee J McGhan1, Barbara A Pockaj, Nabil Wasif, Marina E Giurescu, Ann E McCullough, Richard J Gray.   

Abstract

INTRODUCTION: Excisional biopsy is currently recommended for atypical ductal hyperplasia (ADH) diagnosed on core needle breast biopsy (CNB), due to risk of upstaging to invasive or in situ carcinoma (DCIS). The study goal was to identify patients who may potentially forego excisional biopsy if the risk of upstaging is low.
METHODS: We conducted a retrospective review of patients diagnosed with ADH on CNB who underwent excisional biopsy at one institution (5/2000-5/2011). We evaluated the upstaging rate and clinicopathologic factors associated with increased upstaging risk.
RESULTS: A total of 114 cases of ADH were diagnosed on CNB. The median patient age was 64 years. On mammography, a mass/density/area of distortion was present in 23 % of cases; calcifications were present in 77 %. Most biopsies (79 %) were performed stereotactically. Twenty lesions (18 %) were upstaged to infiltrating carcinoma (5 %) or DCIS (13 %). Residual ADH was present in 43 biopsies (38 %). On univariate analysis, significant variables associated with upstaging included age >50 years, a mass lesion on mammography, and shorter length of biopsy core (p < 0.05). No patient ≤50 years of age was upstaged. Three patients who were not upstaged (3 %) developed ipsilateral disease (2 DCIS and 1 infiltrating ductal carcinoma) at a median time of 37 months.
CONCLUSIONS: The rate of upstaging when ADH is diagnosed on CNB at our institution is 18 %, and routine excisional biopsy is currently recommended for all patients. However, patients <50 years old with focal atypia only and no residual calcifications postbiopsy may represent a low-risk group who could potentially avoid excisional biopsy.

Entities:  

Mesh:

Year:  2012        PMID: 22878619     DOI: 10.1245/s10434-012-2575-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

Review 1.  How Do We Approach Benign Proliferative Lesions?

Authors:  Faina Nakhlis
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

Review 2.  Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review.

Authors:  Kelly L Mooney; Lawrence W Bassett; Sophia K Apple
Journal:  Mod Pathol       Date:  2016-08-19       Impact factor: 7.842

3.  Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center.

Authors:  Gelareh Farshid; Suzanne Edwards; James Kollias; Peter Grantley Gill
Journal:  Mod Pathol       Date:  2017-11-03       Impact factor: 7.842

4.  Atypical hyperplasia of the breast--risk assessment and management options.

Authors:  Lynn C Hartmann; Amy C Degnim; Richard J Santen; William D Dupont; Karthik Ghosh
Journal:  N Engl J Med       Date:  2015-01-01       Impact factor: 91.245

5.  Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia.

Authors:  Rhiana S Menen; Nivetha Ganesan; Therese Bevers; Jun Ying; Robin Coyne; Deanna Lane; Constance Albarracin; Isabelle Bedrosian
Journal:  Ann Surg Oncol       Date:  2016-08-29       Impact factor: 5.344

6.  Vacuum assisted breast biopsy (VAB) excision of subcentimeter microcalcifications as an alternative to open biopsy for atypical ductal hyperplasia.

Authors:  Simone Schiaffino; Elena Massone; Licia Gristina; Piero Fregatti; Giuseppe Rescinito; Alessandro Villa; Daniele Friedman; Massimo Calabrese
Journal:  Br J Radiol       Date:  2018-02-23       Impact factor: 3.039

Review 7.  Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended?

Authors:  Marco Lucioni; Chiara Rossi; Pascal Lomoro; Francesco Ballati; Marianna Fanizza; Alberta Ferrari; Carlos A Garcia-Etienne; Emanuela Boveri; Giulia Meloni; Maria Grazia Sommaruga; Elisa Ferraris; Angioletta Lasagna; Elisabetta Bonzano; Marco Paulli; Adele Sgarella; Giuseppe Di Giulio
Journal:  Eur Radiol       Date:  2020-08-20       Impact factor: 5.315

8.  Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade.

Authors:  Roberto Lo Gullo; Kerri Vincenti; Carolina Rossi Saccarelli; Peter Gibbs; Michael J Fox; Isaac Daimiel; Danny F Martinez; Maxine S Jochelson; Elizabeth A Morris; Jeffrey S Reiner; Katja Pinker
Journal:  Breast Cancer Res Treat       Date:  2021-01-20       Impact factor: 4.872

9.  Absence of Residual Microcalcifications in Atypical Ductal Hyperplasia Diagnosed via Stereotactic Vacuum-Assisted Breast Biopsy: Is Surgical Excision Obviated?

Authors:  Inyoung Youn; Min Jung Kim; Hee Jung Moon; Eun-Kyung Kim
Journal:  J Breast Cancer       Date:  2014-09-30       Impact factor: 3.588

10.  Validation of a scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia using an ultrasound-guided core needle biopsy.

Authors:  Jisun Kim; Wonshik Han; Eun-Young Go; Hyeong-Gon Moon; Soo Kyung Ahn; Hee-Chul Shin; Jee-Man You; Jung Min Chang; Nariya Cho; Woo Kyung Moon; In Ae Park; Dong-Young Noh
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.